Avalo Therapeutics Highlights Potential of AVTX-009 in HS

The latest announcement is out from Avalo Therapeutics ( (AVTX) ).

On June 20, 2025, Avalo Therapeutics released an updated investor presentation highlighting the potential of its lead compound, AVTX-009, which shows promise in treating hidradenitis suppurativa (HS) with a higher affinity and longer half-life compared to existing treatments. The Phase 2 LOTUS trial for AVTX-009 is currently enrolling, with topline data expected by mid-2026, and the HS market is projected to grow significantly, offering substantial opportunities for Avalo and its stakeholders.

The most recent analyst rating on (AVTX) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Avalo Therapeutics stock, see the AVTX Stock Forecast page.

Spark’s Take on AVTX Stock

According to Spark, TipRanks’ AI Analyst, AVTX is a Neutral.

Avalo Therapeutics’ overall stock score reflects significant financial challenges, offset partially by positive corporate events and moderate technical indicators. Financial instability is the primary concern, but strategic developments in leadership and promising pipeline updates offer some hope for future performance.

To see Spark’s full report on AVTX stock, click here.

More about Avalo Therapeutics

Avalo Therapeutics, Inc. operates in the biotechnology industry, focusing on developing novel IL-1β therapies aimed at addressing unmet medical needs in immune-mediated inflammatory diseases. The company’s lead compound, AVTX-009, is designed to treat hidradenitis suppurativa (HS), a chronic inflammatory skin condition.

Average Trading Volume: 73,123

Technical Sentiment Signal: Sell

Current Market Cap: $51.54M

For an in-depth examination of AVTX stock, go to TipRanks’ Overview page.